 Karyopharm is still reporting growth, but the market continues to punish KPTI to fresh 52-week lows. I take a look at the companys Q3 earnings report. XPOVIO delivered strong year-over-year growth with 32M, up from 26.7M in Q3 of last year, representing 20 growth year-over-year. 